Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Novartis
Hunan Province Tumor Hospital
Fudan University
Fudan University
Eastern Cooperative Oncology Group
Memorial Sloan Kettering Cancer Center
Innovent Biologics (Suzhou) Co. Ltd.
Helix BioPharma Corporation
National Cancer Institute (NCI)
Swiss Cancer Institute
Morphotek
Shanghai Chest Hospital
Swiss Cancer Institute
Swiss Cancer Institute
Swiss Cancer Institute
Wake Forest University Health Sciences
Shanghai Pulmonary Hospital, Shanghai, China
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Anhui Provincial Hospital
Radiation Therapy Oncology Group
Guangzhou Medical University
National Cancer Institute (NCI)
Radiation Therapy Oncology Group
Spectrum Pharmaceuticals, Inc
SWOG Cancer Research Network
National Cancer Institute (NCI)
SWOG Cancer Research Network
SWOG Cancer Research Network
European Organisation for Research and Treatment of Cancer - EORTC
Swiss Cancer Institute
National Cancer Institute (NCI)